gdc
PSSGuide_2020
Gastric Cancer

Gastric / Gastroesophageal Junction Cancer

Here are the drugs and financial support services available to patients receiving treatment for Gastric / Gastroesophageal Junction Cancer.

Cyramza (ramucirumab)

Drug company: Eli Lilly
866-472-8663

Cyramza is a human VEGF receptor 2 antagonist used as a single drug, or in combination with paclitaxel, for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that progressed after chemotherapy.

Lilly PatientOne offers 2 financial assistance programs for patients using Cyramza:

Lilly PatientOne Co-pay Program

For patients with private insurance who cannot afford their copay, this program provides up to $25,000 annually so that the patient pays no more than $25 per dose of Cyramza.

Lilly Cares Foundation Patient Assistance Program

For eligible patients with no medical insurance (or those whose insurance does not cover drug therapy) and who have an annual household income of up to $62,450 for 1 person; $84,550 for 2 people; $106,650 for 3 people; $128,750 for 4 people; $150,850 for 5 people; $172,950 for 6 people, this program provides Cyramza at no cost.

Herceptin (trastuzumab)

Drug company: Genentech
866-422-2377

Herceptin is a HER2 receptor antagonist used for the treatment of patients with HER2-overexpressing, metastatic gastric or gastroesophageal junction adenocarcinoma.

Genentech Access Solutions offers 2 financial assistance programs for patients using Herceptin:

Genentech BioOncology Co-pay Assistance Program

Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Herceptin, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 120 days before enrollment in this program.

Genentech Patient Foundation

This foundation provides Herceptin free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria. For households with more than 4 people, add $25,000 per each additional member. Herceptin is also provided free for patients who are unable to afford their out-of-pocket costs and cannot find other financial assistance.

Kanjinti (trastuzumab-anns)

Drug company: Amgen
888-427-7478

Kanjinti, biosimilar to Herceptin, is a HER2/neu receptor antagonist used to treat patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Amgen offers 2 financial assistance programs for patients who have been prescribed Kanjinti:

Amgen FIRST STEP Program

With this program, eligible patients with private insurance will pay $0 for the first dose of Kanjinti and $5 for each subsequent dose, with a maximum annual benefit of $20,000.

Amgen Safety Net Foundation

Patients with limited or no drug coverage and patients with Medicare Part D who satisfy the income eligibility requirements may receive Kanjinti for free.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1 inhibitor used for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that is expressing PD-L1, as determined by an FDA-approved test, and is progressing during or after 2 or more lines of therapy, including fluoropyrimidine- and platinum-containing chemo­therapy, and when appropriate, HER2-targeted therapy.

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000 for patients with an income up to 700% of the federal poverty level, and $10,000 for patients with an income above 700% of the federal poverty level.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $62,450 or less for individuals, $84,550 or less for a couple, or $128,750 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.

Lonsurf (trifluridine + tipiracil) Tablets

Drug company: Taiho
844-824-4648

Lonsurf is a combination of a nucleoside metabolic inhibitor and a thymidine phosphorylase inhibitor that is used for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma in patients who received at least 2 previous lines of chemotherapy that included a fluoropyrimidine, a platinum, and either a taxane or irinotecan, and if appropriate, therapy that targets the HER2/neu gene.

Taiho offers 2 financial assistance programs for patients who have been prescribed Lonsurf:

Taiho Oncology Patient Support Co-pay Card

Patients with private insurance may be eligible to receive a copay card to help them pay out-of-pocket cost of $0 for Lonsurf.

Taiho Oncology Patient Support Program

This program may provide Lonsurf for free to patients who have no insurance or insufficient prescription coverage and insufficient financial resources.

Ogivri (trastuzumab-dkst) Injection

Drug company: Mylan
833-695-2623

Ogivri, a biosimilar to Herceptin, is a HER2/neu receptor antagonist used for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

Mylan offers 2 financial assistance programs for patients who have been prescribed Ogivri:

Mylan Advocate Co-Pay Assistance Program

This program pays the full out-of-pocket cost of Ogivri for eligible patients who have private insurance.

Mylan Advocate Patient Assistance

Uninsured patients who cannot afford the cost of Ogivri may be eligible to receive Ogivri for free. Eligibility requirements include US residency, income limits, and other factors.

Table. Drugs Prescribed for Gastric/Gastroesophageal Junction Cancer

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services


    Drug name (generic name)
  • Kanjinti (trastuzumab-anns)
  • Drug company
  • Amgen
  • Indication
  • Treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma
  • Patient support services
  • Amgen FIRST STEP Program
    888-657-8371

    Amgen Safety Net Foundation
    888-762-6436

    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • Locally advanced or metastatic gastric or gastroesophageal junction adeno­carci­noma that is expressing PD-L1 and is progressing during or after 2 or more lines of therapy, including fluoropyrimidine- and platinum-containing chemotherapy, and when appropriate, HER2-targeted therapy
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    855-257-3932

    Drug name (generic name)
  • Lonsurf (trifluridine + tipiracil) Tablets
  • Drug company
  • Taiho
  • Indication
  • Treatment of adults with metastatic gastric or gastroesophageal junction adeno-carcinoma after at least 2 lines of chemotherapy with a fluoropyrimidine, a platinum, and a taxane or irinotecan, and if appropriate, targeted therapy for HER2/neu
  • Patient support services
  • Taiho Oncology Patient Support Co-pay Card
    844-824-4648

    Taiho Oncology ­Patient Support ­Program
    844-824-4648


Last modified: March 9, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country